Prognostic impact of molecular analyses in adenoid cystic carcinomas of the salivary gland

Onkologie

Volumn 24, Issue 3, 2001, Pages 273-277

  Preisegger, K H ^a,b,c   Beham, A ^a,b,c   Kopp, S ^a,b,c   Jessernigg, G ^a,b,c   Gugl, A ^a,b,c   Stammberger, H ^a,b,c  

^a Institut für Allgemeine und Experimentelle   (Austria)

^b Klinische Abteilung für Pädiatrische Hämato Onkologie   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adenoid cystic carcinoma: prognosis; p53; Salivary gland carcinoma

Indexed keywords

DNA TOPOISOMERASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; PROTEIN BCL 2; PROTEIN P53;

ADENOID CYSTIC CARCINOMA; ARTICLE; DISEASE ASSOCIATION; DISEASE MARKER; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTEIN ANALYSIS; SALIVARY GLAND CARCINOMA;

CARCINOMA, ADENOID CYSTIC; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034919875     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055091     Document Type: Article

References (22)

1. Tumors of the salivary glands
2. The World Health Organization's histological classification of salivary gland tumors: A commentary on the second edition
3. Histopathologic grading of salivary gland neoplasms: III. Adenoid cystic carcinomas
4. Prognostic factors for adenoid cystic carcinomas of the head and neck: A retrospective evaluation of 96 cases
5. The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma
6. Loss of heterozygosity and microsatellite alterations in p53 and RB genes in adenoid cystic carcinoma of the salivary gland
7. P53 mutations in human cancers
8. The Bcl-2 protein family: Arbiters of cell survival
9. Accumulation of p53 as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, floururacil, and prednisone for breast cancer
10. The clinical relevance of multidrug resistance
11. Glutathione system, topoisomerase II level and mdr phenotype in AML before treatment and at relapse
12. Hepatitis delta virus infektion: Eine immunhistochemische studie
13. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
14. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers
15. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
16. Bcl-2 antisense therapy in human cancer
17. Antitopoisomerase drug action and resistance
18. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(-4-[1 piperidinol]-1-piperidino)-carbonyloxy-captothecin against pediatric and adult central nervous system tumor xenografts
19. Evidence for the expression of radiation induced potentially lethal damage beeing a p-53 dependent process
20. Clinical multidrug resistance in cancer: A multifactorial problem
21. Apoptosis and chemotherapy resistance
22. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27, is predictive of the response to induction chemotherapy